← All trials
NCT06225752
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2024
- Primary completion
- Apr 30, 2026
- Completion date
- Oct 31, 2026
- First posted
- Jan 26, 2024
- Last posted
- Jul 15, 2024
- Enrollment
- 5452
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Wannan Medical CollegeLead sponsor
- Capital Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.